Undiluted IV Push Valproic Acid Shows Favorable Safety Across 5500 Doses
This large single-center cohort adds real-world safety data supporting rapid undiluted intravenous push administration of valproic acid across a broad dosing range, relevant to pharmacists managing seizures, status epilepticus, and headache in acute care.
Undiluted IV push valproic acid proves safe for rapid seizure treatment.
Traditional intravenous infusion delays of valproic acid (VPA) can hinder emergent treatment for seizures and headaches. Rapid intravenous push (IVP) administration could mitigate this issue. In 570 patients receiving 5546 doses of undiluted IVP VPA, only three non-probable adverse events occurred, indicating favorable safety and tolerability. This study supports the use of undiluted IVP for VPA in urgent clinical settings, but as a retrospective study, its findings should be corroborated by further prospective trials. Undiluted IVP VPA may be a safe option for rapid administration in time-sensitive situations like seizures.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Rollins S, Radosevich JJ, Sammani N, Haller JT
Citation:Rollins S, Radosevich JJ, Sammani N, et al. Rapid administration of undiluted IV push valproic acid. Journal of neurology. 2026;273(8). doi:10.1007/s00415-026-13983-y